Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX Liquid Cooling Systems Announces New 8MW Coolant Distribution Unit, Optimized for 45°C Warm-Water Cooling in Next-Gen NVIDIA Vera Rubin AI Deployments23.1.2026 15:18:00 EET | Press release
DCX Liquid Cooling Systems is proud to announce the second generation Facility Distribution Unit (FDU V2AT2). Designed to support the infrastructure shift driven by AI deployments at scale, new CDU supports 45°C warm-water cooling for NVIDIA’s NVL72 GB200 / GB300 Blackwell and Vera Rubin architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123068139/en/ The Facility Coolant Distribution Unit—the new generation of liquid cooling for hyperscale data centers. FDU V2AT2 delivers up to 8.15MW of heat transfer capacity while providing record breaking flowrate, enabling 45°C warm-water operation—temperature level that can eliminate the need for chillers on the heat-rejection side in many deployments. This new cooling system has also built in most capable heat exchanger in the industry, which further enables heat reuse and chillerless heat transfer. “As the datacenter industry transitions to AI factories, operators need
HUMAIN and Infra Announce AI and Digital Financing Framework Agreement23.1.2026 15:01:00 EET | Press release
HUMAIN and the National Infrastructure Fund (“Infra”) announced on the sidelines of the World Economic Forum (WEF) Annual Meeting 2026 in Davos, Switzerland, a Strategic Financing Framework Agreement of up to $1.2 billion to support the expansion of AI and digital infrastructure projects in the Kingdom of Saudi Arabia. The Framework Agreement outlines non-binding financing terms for HUMAIN’s development of up to 250 MW of hyperscale AI data center capacity. These data centers will deploy leading edge GPUs for AI training and inference and support HUMAIN’s local, regional and global customers. In addition, Infra and HUMAIN have agreed to explore the establishment of an AI data center investment platform. This would be anchored by the two organizations and structured to facilitate participation by global and local institutional investors to support further scaling of HUMAIN’s AI strategy. Today’s Framework Agreement underscores Infra’s key role in partnering with its counterparts to acce
Cyclic Materials Secures USD $75M Series C Funding to Fast-Track Local and Resilient Rare Earths Supply at Global Scale23.1.2026 14:00:00 EET | Press release
Cyclic Materials today announced it has closed an over-subscribed USD $75 million Series C equity round, its largest to date, scaling up operations across the US and Europe and accelerating Canada-based research and development footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123519008/en/ Cyclic Materials’ Mesa, Arizona site, the very first scale-up of a commercial plant for recycling and local production of rare earths in the US, with a focus on heavy and light rare earth magnets. The recycling of magnet-containing end-of-life (EOL) scrap and magnet production waste is the fastest way to the production of magnet rare earth elements (REEs) in Western countries, and it can provide unique access to heavy rare earth elements, which are much less commonly available through mining deposits in the Western world. Positioned as both a diversified source of supply and a circular solution that interrupts waste streams, Cy
SLB Announces Fourth-Quarter and Full-Year 2025 Results, Increases Dividend and Commits to Return More Than $4 Billion to Shareholders in 202623.1.2026 13:50:00 EET | Press release
SLB (NYSE: SLB) today announced results for the fourth-quarter and full-year 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121043645/en/ The exterior of the SLB headquarters in Houston, Texas. Fourth-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeDec. 31, 2025Sept. 30, 2025Dec. 31, 2024SequentialYear-on-yearRevenue $9,745 $8,928 $9,284 9% 5% Income before taxes - GAAP basis $943 $1,000 $1,387 -6% -32% Income before taxes margin - GAAP basis 9.7% 11.2% 14.9% -153 bps -526 bps Net income attributable to SLB - GAAP basis $824 $739 $1,095 12% -25% Diluted EPS - GAAP basis $0.55 $0.50 $0.77 10% -29% Adjusted EBITDA* $2,331 $2,061 $2,382 13% -2% Adjusted EBITDA margin* 23.9% 23.1% 25.7% 83 bps -175 bps Pretax segment operating income* $1,807 $1,626 $1,918 11% -6% Pretax segment operating margin* 18.5% 18.2% 20.7% 33 bps -211 bps Net income attributable to SLB, excluding charges & cr
“And I Chose to Live” The Blind Sailor Mitsuhiro Iwamoto Takes the Stage at WEF23.1.2026 10:00:00 EET | Press release
Mitsuhiro Iwamoto, a blind Japanese sailor based in San Diego, delivered a speech at the World Economic Forum Annual Meeting 2026 on January 21 (local time). He is undertaking the world’s first solo, non-stop trans-Pacific crossing by a blind person as part of the “Blind Sailor Single-Handed Pacific Crossing Project 2027.” WEF URL: https://www.weforum.org/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121469502/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific In the spring of 2027, he will attempt a solo, non-stop trans-Pacific crossing, sailing a 28-foot yacht single-handedly from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making any port calls. Project URL: https://hiros-choice.com/ The theme of his speech was “Sailing Through Barriers.” He spoke about how, since losing his sight at the age of 13, he has consistently chosen challenge as his
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom